Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria.

Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria.

老虎证券老虎证券2026/02/25 12:22
Show original
This significant progress marks a solid step forward for the therapy in the critical phase of validating its efficacy and safety, laying a strong foundation for subsequent data analysis and regulatory submissions.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Meta (META.US) AI shopping assistant Muse tests e-commerce, Amazon (AMZN.US) faces potential impact on nearly $70 billion advertising business

Meta Platforms (META.US) has launched its new AI shopping assistant, Muse, which is emerging as a potential threat to Amazon. Muse may challenge the e-commerce giant’s dominance in online shopping and its nearly 70 billion USD advertising business.

智通财经•2026/11/01 23:16
Meta (META.US) AI shopping assistant Muse tests e-commerce, Amazon (AMZN.US) faces potential impact on nearly $70 billion advertising business